Key Highlights

  • The net loss shrank to USD 96.3 million, or USD 0.57 per share, in the third quarter, down from USD 163.1 million, or USD 1.17, a year earlier.
  • Cash, cash equivalents and investments came to about USD 901.3 million on September 30, 2026, and the company carries no debt.
  • Research and development expense dropped to USD 80.0 million from USD 151.5 million, since the year-earlier quarter included a USD 75.0 million milestone payment.
  • Total Revenue came to negative USD 0.2 million in the quarter, versus positive USD 0.2 million a year earlier.

Lower Spending Narrows the Loss

Vir Biotechnology (NASDAQ:VIR) submitted its quarterly filing on November 4, 2026, for the quarter that ended September 30, 2026. The company is clinical stage and pursues therapies for chronic hepatitis Delta and cancer. Operating costs totaled USD 104.5 million, compared with USD 173.7 million. Contract Manufacturing climbed to USD 25.8 million from USD 9.6 million, yet a USD 75.0 million milestone booked for VIR-5525 in the prior-year period, along with collaborator cost recoveries, pulled down the license line. Through nine months the net loss shrank to USD 141.9 million from USD 395.1 million, supported by USD 239.3 million of license income from the Astellas deal. Selling, general and administrative spending rose to USD 24.4 million from USD 22.2 million because of heavier advisory and legal bills, and interest income reached USD 9.3 million.

ECLIPSE 1 Readout Is the Near-Term Catalyst

Pivotal ECLIPSE 1 topline readout in chronic hepatitis delta is expected during the fourth quarter of 2026, while ECLIPSE 2 and ECLIPSE 3 are slated for the first quarter of 2027. Those studies evaluate elebsiran paired with tobevibart. Extended Phase 2 SOLSTICE findings will be shown on November 8 at a liver meeting. In oncology, prostate cancer candidate VIR-5500 received FDA Fast Track status, and multiple pivotal studies are expected to start in 2027. The HER2-directed VIR-5818 will add backfill cohorts following FDA input, and that same candidate is in dose escalation alongside pembrolizumab. The EGFR-directed VIR-5525 is still enrolling patients.

Gilead Cash Arrives After Quarter End

October 2026 brought USD 90 million from Gilead Sciences: a USD 65 million upfront payment plus a USD 25 million Equity purchase. Vir may receive up to USD 45 million in near-term preclinical milestones and up to USD 1.74 billion in later milestones, along with royalties. Leadership thinks current cash and investments can carry operations for at least a year from the filing date, yet additional Capital might be required, potentially diluting shareholders. Clinical results are the principal hazard. A new CFO started on October 5, 2026. Nine-month operating cash burn was USD 115.1 million, down from USD 365.9 million, and the accumulated Deficit stands at USD 1.3 billion.

Where Things Stand

The runway covers the readout window, per management's 12-month view. Vir Biotechnology (NASDAQ:VIR) enters the period with USD 901.3 million in cash and investments, USD 90 million more from Gilead and a smaller loss. ECLIPSE 1 topline data are due in the fourth quarter of 2026, with ECLIPSE 2 and 3 following in the first quarter of 2027. The company has yet to generate product sales, and trial outcomes could move the outlook sharply in either direction. Next markers are the November 8 SOLSTICE presentation and the ECLIPSE 1 readout. The accumulated deficit is USD 1.3 billion.